GlassScriptPhysician profile
Murali G Murty
NPI 1013184423
$17,051.40
in general payments reported to CMS, 2019-2025
68 companies · $5,276 in 2025
The $5,276 reported for 2025 was more than what 95% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $1,055 · 2021: $2,138 · 2022: $2,329 · 2023: $2,073 · 2024: $2,747 · 2025: $5,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,938 · Travel and Lodging: $1,138 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,937.94 |
| Travel and Lodging | $1,138.39 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $2,596.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,307.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,035.35 | 2019-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $825.40 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $810.26 | 2019-2025 | |
| Amgen INC. | $799.95 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Janssen Biotech, INC. | $626.12 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $612.06 | 2019-2025 | |
| Pfizer INC. | $603.56 | 2020-2025 | |
| Novocure INC. | $574.39 | 2022-2025 | Optune Lua (Novottf-200t), Optune Gio |
| E.R. Squibb & Sons, L.L.C. | $511.14 | 2019-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $419.72 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $378.03 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $349.34 | 2019-2025 | |
| Genmab U.S., INC. | $332.05 | 2024-2025 | Tivdak, Epkinly |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $305.09 | 2019-2024 | Alecensa, Tecentriq, Gavreto |
| Puma Biotechnology, INC. | $286.81 | 2019-2025 | Nerlynx |
| Jazz Pharmaceuticals INC. | $283.28 | 2021-2025 | |
| Eisai INC. | $251.85 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $250.15 | 2023-2025 | Orgovyx |
| Incyte Corporation | $201.15 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $196.93 | 2020-2025 | Iclusig, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $190.30 | 2020-2023 | Imbruvica, Epkinly |
| Seagen INC. | $189.63 | 2020-2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $184.12 | 2019-2024 | Onivyde, Somatuline Depot, Tazverik |
| Glaxosmithkline, LLC. | $165.03 | 2021-2025 | Zejula, Ojjaara, Jemperli |
| Visionrt, INC. | $154.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.43 | 2019-2024 | Gilotrif |
| Karyopharm Therapeutics INC. | $147.14 | 2020-2024 | Xpovio |
| Celgene Corporation | $145.49 | 2020-2025 | Reblozyl |
| Deciphera Pharmaceuticals INC. | $132.71 | 2023-2025 | Qinlock, Romvimza |
| Blueprint Medicines Corporation | $130.91 | 2021-2025 | Ayvakit |
| Kyowa Kirin, INC. | $120.98 | 2020-2025 | Poteligeo |
| Mirati Therapeutics, INC. | $109.27 | 2023-2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $107.18 | 2019-2024 | Ultomiris |
| Amag Pharmaceuticals, INC. | $103.33 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $101.03 | 2020-2025 | Libtayo |
| Emd Serono, INC. | $95.70 | 2020-2024 | |
| Adc Therapeutics America, INC. | $88.84 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $82.40 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $71.97 | 2019-2022 | |
| Astellas Pharma US INC | $69.02 | 2020-2025 | Vyloy |
| Tersera Therapeutics LLC | $66.39 | 2019-2025 | Zoladex, Quzyttir |
| Clovis Oncology, INC. | $65.99 | 2019-2021 | |
| Exelixis INC. | $64.34 | 2019-2024 | Cabometyx |
| Lexicon Pharmaceuticals, INC. | $56.75 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $54.70 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Springworks Therapeutics, INC. | $51.90 | 2024-2025 | Ogsiveo |
| Acrotech Biopharma INC. | $47.67 | 2021 | |
| Gilead Sciences, INC. | $46.73 | 2021-2024 | |
| Stemline Therapeutics INC. | $46.55 | 2023 | Orserdu |
| Servier Pharmaceuticals LLC | $43.47 | 2025 | |
| Aurobindo Pharma USA, INC. | $41.79 | 2019-2020 | |
| Tactile Systems Technology INC | $40.39 | 2019 | |
| Epizyme, INC. | $37.72 | 2020-2021 | |
| Sobi, INC | $36.37 | 2022-2023 | |
| Syndax Pharmaceuticals, INC. | $32.29 | 2025 | |
| Pharmaessentia USA Corporation | $31.94 | 2025 | Besremi |
| Advanced Accelerator Applications | $30.42 | 2020 | |
| Tolmar, INC. | $22.35 | 2023 | |
| Mylan Institutional INC. | $20.61 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.64 | 2025 | Alymsys |
| Morphosys, US INC. | $19.48 | 2021 | |
| Tesaro, INC. | $18.58 | 2019 | |
| G1 Therapeutics, INC. | $18.40 | 2021 | |
| Adaptive Biotechnologies Corporation | $16.10 | 2025 | Clonoseq |
| Myovant Sciences INC. | $14.95 | 2021 | |
| Verastem, INC. | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murali Murty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.